Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your Favored pizza beating - 2How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- 3FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 4Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
- 54 Famous Attractions at Disneyland
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- A definitive Cruiser Standoff: Decision in favor of Your #1 Ride
- Belarusian parliament passes a bill to crack down on LGBTQ+ rights
- Child influencers helped power a booming industry. It's time for a reckoning.
- Outer space conditions hamper sperm's ability to navigate toward an egg
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
- UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- 25 Most Beautiful Villages in France You Can Actually Visit
- Tech Devices 2023: The Most blazing Arrivals of the Year
